Estimation of CML incidence: Disagreement between national cancer registry and health claims data system in Taiwan

Chang, Chia-Wen; Lee, Kungko; Yang, Yi‐Hsin; Lin, Min-Ting; Hsu, Chien‐Ning

doi:10.1016/j.leukres.2010.12.034

Cited by 13 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, such differences have been shown in other haematological cancers such as chronic lymphocytic leukaemia and acute promyelocytic leukaemia [22,23]. In CML, several reports suggest that the incidence of CML is lower in some Asian countries [16,24]. Thus, Chen et al, analysing the incidence of CML in different ethnical subgroups within the USA, showed a lower incidence of CML in Asians as compared to Caucasians [17].…”

Section: Incidencementioning

confidence: 99%

“…Incidence of CML in the total adult population Published data on the annual incidence of CML varies from as low as 0.4/100,000 persons in some non-Western countries to 1.75/100,000 in the USA [7][8][9][15][16][17][18][19]. As the incidence of CML increases by age, some of these variations are due to significant differences in the age distributions of the investigated populations (e.g.…”

Section: Incidencementioning

confidence: 99%

See 1 more Smart Citation

Epidemiology of chronic myeloid leukaemia: an update

2015

View full text Add to dashboard Cite

National and regional population-based registries are, provided diagnostic accuracy and full coverage of the target population, indispensible tools for epidemiological research. Chronic myeloid leukaemia (CML) registries with more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7-1.0/100,000, a median age at diagnosis of 57-60 years and a male/female ratio of 1.2-1.7. The incidence of CML has been stable over time. Worldwide, variations in the reported incidence of CML may be due to methodological issues, but a true difference between different geographical areas and/or ethnical subgroups cannot be excluded. The prevalence of CML is not well known but has been estimated to be 10-12/100,000 inhabitants with a steady increase due to the dramatic improvement in survival of these patients. In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased. The importance of socio-economic factors and health-care setting for outcome and the possible increased risk of secondary cancer in CML are areas of ongoing research.

show abstract

Section: Incidencementioning

confidence: 99%

Section: Incidencementioning

confidence: 99%

Epidemiology of chronic myeloid leukaemia: an update

2015

View full text Add to dashboard Cite

show abstract

“…A widely divergent annual incidence estimate of chronic myeloid leukemia (CML) is about 0.4-1.0 cases per 100,000 persons in the Asia-Pacific region. 2 And there are more than 4 million cases of leukemia in China.…”

Section: Introductionmentioning

confidence: 99%

<p>Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis</p>

Gao

Shen

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: Leukemia threatens so many lives around the world. Dihydroartemisinin (DHA), as a typical derivative of artemisinin (ART), can efficiently inhibit leukemia, but the controversial mechanisms are still controversial. Many reports showed that tumor cells acquire energy through the glycolysis pathway, pyruvate kinase M2 (PKM2) plays a crucial role in regulating glycolysis. However, it is unclear whether PKM2 or other key molecules are involved in DHA induced cytotoxicity in leukemia cells. Thus, this paper systematically investigated the anticancer effect and mechanism of DHA on human chronic myeloid leukemia K562 cells. Methods: In vitro, cytotoxicity was detected with CCK-8. Glucose uptake, lactate production and pyruvate kinase activity were investigated to evaluate the effect of DHA on K562 cells. To elucidate the cellular metabolism alterations induced by DHA, the extracellular acidification rate was assessed using Seahorse XF96 extracellular flux analyzer. Immunofluorescence, real-time PCR, and Western blotting were used to investigate the molecular mechanism. Results: We found that DHA prevented cell proliferation in K562 cells through inhibiting aerobic glycolysis. Lactate product and glucose uptake were inhibited after DHA treatment. Results showed that DHA modulates glucose uptake through downregulating glucose transporter 1 (GLUT1) in both gene and protein levels. The cytotoxicity of DHA on K562 cells was significantly reversed by PKM2 agonist DASA-58. Pyruvate kinase activity was significantly reduced after DHA treatment, decreased expression of PKM2 was confirmed in situ. Conclusion: The present study implicated that DHA inhibits leukemia cell proliferation by regulating glycolysis and metabolism, which mediated by downregulating PKM2 and GLUT1 expression. Our finding might enrich the artemisinins' antitumor mechanisms.

show abstract

“…Chronic myelogenous leukemia (CML) is a neoplastic disease of hematopoietic stem cells that has an annual incidence of 0.4-1.75/100,000 [11][12][13][14][15] and accounts for 15% of adult leukemia.…”

Section: Introductionmentioning

confidence: 99%

The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey

Wang

Guo

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world. So far, there is rare data on the prevalence of COVID-19 in patients with chronic myelogenous leukemia (CML). We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients. Methods In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected. Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020. The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history, symptoms(fever, cough, shortness of breath, etc) during the epidemic. Additional clinical data was collected on respondents suspected or confirmed to have COVID-19. We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients. Data were compared between the CML patients with optimal response and those with non-optimal response. The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020. Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19 . Findings Of 392 respondents, 223( 56.9%) were males, and 240( 61.2%) were 50 years or younger. Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc. In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact. 12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment. 1 patient was clinically diagnosed and succumbed. 1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19. Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19. Interpretation While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak. Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2. Older patients with comorbidities are at increased risk of death. Dan-Yu Wang, Jing-Ming Guo, Zhuang-Zhi Yang Co first author Dan-Yu Wang,Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen Guangdong, China,E-mail: 15818662864@139.com Jing-Ming Guo, Department of Hematology,Yi Chang Central People's Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei, China,E-mail:gjm425@163.com Zhuang-Zhi Yang, Department of Hematology,Suizhou Central Hospital, Suizhou Hubei, China,E-mail:yzhzh88@163.com Correspondence author: Guo-Lin Yuan, MD, Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China. E-mail: yuanguo1973@163.com Li Meng, MD, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan Hubei, China. E-mail: mengli@tjh.tjmu.edu.cn Wei-Ming Li, MD, Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of science and Technology, Wuhan Hubei, China. E-mail: lee937@126.com

show abstract

Estimation of CML incidence: Disagreement between national cancer registry and health claims data system in Taiwan

Cited by 13 publications

References 9 publications

Epidemiology of chronic myeloid leukaemia: an update

Epidemiology of chronic myeloid leukaemia: an update

<p>Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis</p>

The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey

Contact Info

Product

Resources

About